Search Within

GDMT, Medicine

  1. "Early Drug Development Service"
Formats
  1. Journal Article (42)
  2. Meeting Abstract (29)
  3. Book Section (1)
Groups
  1. Department of Medicine (72)
  2. Early Drug Development Service (72)
  3. Gynecologic Medicine Service (72)
  4. Gynecology Disease Management Team (72)
  5. Solid Tumor Oncology Division (72)
  6. Epidemiology and Biostatistics (35)

More Groups

People
  1. David Hyman (61)
  2. Carol Aghajanian (36)
  3. Rachel Grisham (33)
  4. Vicky Makker (25)
  5. Martee Hensley (24)
  6. Alexia Iasonos (23)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (1)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (21)
  2. Gynecologic Oncology (10)
  3. Clinical Cancer Research (8)
  4. JCO Precision Oncology (5)
  5. Annals of Oncology (3)
  6. Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (26)
  2. Elsevier Inc. (13)
  3. American Association for Cancer Research (12)
  4. Lippincott Williams & Wilkins (5)
  5. Oxford University Press (3)
  6. Springer (3)

More Publishers

Results (72)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical utility of prospective molecular characterization in advanced endometrial cancer
    Journal Article

    Soumerai, T. E.; Donoghue, M. T. A.; Bandlamudi, C.; Srinivasan, P.; Chang, M. T.; Zamarin, D.; Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Tew, W. P.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Phase I study of MEDI3617, a selective angiopoietin-2 inhibitor alone and combined with carboplatin/paclitaxel, paclitaxel, or bevacizumab for advanced solid tumors
    Journal Article

    Hyman, D. M.; Rizvi, N.; Natale, R.; Armstrong, D. K.; Birrer, M.; Recht, L.; Dotan, E.; Makker, V.; Kaley, T.; Kuruvilla, D.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer
    Journal Article

    LaVigne, K.; Hyman, D. M.; Zhou, Q. C.; Iasonos, A.; Tew, W. P.; Aghajanian, C.; Makker, V.; Hensley, M. L.; Konner, J.; Grisham, R. N.; more...
    International Journal of Gynecological Cancer (2018)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Somatic mutations in homologous recombination pathway genes in ovarian cancer
    Meeting Abstract

    Aghajanian, C.; DeLair, D.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Makker, V.; O'Cearbhaill, R. E.; Sabbatini, P.; Soumerai, T.; Charen, A. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer
    Journal Article

    Weigelt, B.; Comino-MeĢndez, I.; de Bruijn, I.; Tian, L.; Meisel, J. L.; Garcia-Murillas, I.; Fribbens, C.; Cutts, R.; Martelotto, L. G.; Ng, C. K. Y.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
    Journal Article

    Zehir, A.; Benayed, R.; Shah, R. H.; Syed, A.; Middha, S.; Kim, H. R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S. M.; more...
    Nature Medicine (2017)

    Fulltext@MSK | Save